Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,058 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | terminated | Phase 1 | 17 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT02208362 | Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | active not recruiting | Phase 1 | 65 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03030066 | Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas | completed | Phase 1 | 47 | Daiichi SankyoINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07732413 | Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer | not yet recruiting | Phase 1 | 30 | Lumos PharmaINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03922555 | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | recruiting | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 1 | 200 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 22, 2026 | clinicaltrials |
| NCT06973096 | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06672575 | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02359565 | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | active not recruiting | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 2 | Jul 20, 2026 | clinicaltrials |
| NCT04900792 | A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma(XACT-Fe-GBM-01) | active not recruiting | Phase 1 | 16 | Bryan AllenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03423628 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | active not recruiting | Phase 1 | 159 | AstraZenecaINDUSTRY | 3 | Jul 17, 2026 | clinicaltrials |
| NCT07710690 | A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 24 | Neuregen Therapeutics Co., Ltd.INDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03830151 | Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors | recruiting | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04656431 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma | recruiting | Phase 1 | 26 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05184816 | A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis | recruiting | Phase 1 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | recruiting | Phase 1 / Phase 2 | 35 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05660369 | CARv3-TEAM-E T Cells in Glioblastoma | recruiting | Phase 1 | 21 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07082868 | A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | recruiting | Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | not yet recruiting | Phase 1 | 15 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702305 | Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma(PNOC018) | terminated | Phase 1 | 4 | University of California, San FranciscoOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07698899 | A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | recruiting | Phase 1 / Phase 2 | 27 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05098613 | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | recruiting | Phase 1 | 68 | University of Colorado, DenverOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma | suspended | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02390518 | Stereotactic Radiosurgery Dose Escalation for Brain Metastases | recruiting | Phase 1 | 86 | University of UtahOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05698199 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | completed | Phase 1 | 10 | Immunomic Therapeutics, Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06455189 | Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06169280 | Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma | suspended | Phase 1 | 20 | Northwestern UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03510208 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 46 | Stanford UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06815029 | Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | recruiting | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674693 | Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases | not yet recruiting | Phase 1 | 29 | NYU Langone HealthOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT02303678 | D2C7 for Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 81 | Darell BignerOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06157541 | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma(TCaP) | active not recruiting | Phase 1 / Phase 2 | 58 | Queensland Institute of Medical ResearchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT00308165 | Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors | completed | Phase 1 | 16 | Columbia UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)(PNOC020) | recruiting | Phase 1 | 28 | University of FloridaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06428045 | STARLITE for Unresectable High-Grade Gliomas(STARLITE) | recruiting | Phase 1 | 24 | University of MiamiOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | recruiting | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05590689 | Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor(ALA-RDTinGBM) | recruiting | Phase 1 / Phase 2 | 34 | Universität MünsterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2026source: clinicaltrials